

Beitrag von Seite 10:

Die Acute Myeloid Leukemia Cooperative Group (AML-CG)

Thomas Büchner, Maria Cristina Sauerland, Achim Heinecke, Jan Braess und Wolfgang Hiddemann

- (1) Multicentre study on intensified remission induction therapy for acute myeloid leukemia. Büchner T, Urbanitz D, Emmerich B, Fischer JT, Fülle HH, Heinecke A, Hossfeld DK, Koeppen KM, Labedzki L, Löffler H, Nowrousian MR, Pfreundschuh M, Pralle H, Rühl H, Wendt FC. *Leuk Res* 1982;6:827-31
- (2) Accumulation of S-phase cells in the bone marrow of patients with acute leukemia by cytosine arabinoside. Büchner T, Barlogie B, Asseburg U, Hiddemann W, Kamanabroo D, Göhde W. *Blut* 1974;28:299-300
- (3) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. Büchner T, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G, et al. *J Clin Oncol* 1985;3:1583-9
- (4) High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Hiddemann W, Kreuzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Büchner T. *Blood*. 1987 Mar;69(3):744-9.
- (5) Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, Fonatsch C, Haase D, Schoch C, Hossfeld D, Lengfelder E, Aul C, Heyll A, Maschmeyer G, Ludwig WD, Sauerland MC, Heinecke A. *Blood*. 1999 Jun 15;93(12):4116-24.
- (6) Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, Schnittger S, Kern W, Tchinda J, Reichle A, Lengfelder E, Staib P, Ludwig WD, Aul C, Eimermacher H, Balleisen L, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W. *J Clin Oncol*. 2006 Jun 1;24(16):2480-9.
- (7) 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A; German AML Cooperative Group. *J Clin Oncol*. 2003 Dec 15;21(24):4496-504.
- (8) *N Engl J Med* 2004;350:2215-6
- (9) Management of acute myeloid leukemia in elderly patients. Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wörmann B, Büchner T. *J Clin Oncol*. 1999 Nov;17(11):3569-76. Review.
- (10) Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P, Grüneisen A, Kern W, Reichle A, Maschmeyer G, Aul C, Lengfelder E, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W. *J Clin Oncol*. 2009 Jan 1;27(1):61-9. Epub 2008 Dec 1.

Beitrag von Seite 12:

Die Aktute Myeloische Leukämie-Studiengruppe (AMLSG)

Rückblick auf die Studienaktivitäten der letzten Jahre und Ausblick

Richard F. Schlenk, Konstanze Döhner, Jürgen Krauter, Arnold Ganzer und Hartmut Döhner

- (1) Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C, Ehninger G, Schaich M, Mohr B, Niederwieser D, Krahl R, Pasold R, Döhner K, Ganzer A, Döhner H, Heil G. *J Clin Oncol*. 2004 Sep 15;22(18):3741-50. Epub 2004 Aug 2.
- (2) Schlenk et al. *BBMT* 2008
- (3) Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. Schaich M, Schlenk RF, Al-Ali HK, Döhner H, Ganzer A, Heil G, Illmer T, Krahl R, Krauter J, Sauerland C, Büchner T, Ehninger G. *Haematologica*. 2007 Jun;92(6):763-70.
- (4) Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. Krauter J, Wagner K, Schäfer I, Marschalek R, Meyer C, Heil G, Schaich M, Ehninger G, Niederwieser D, Krahl R, Büchner T, Sauerland C, Schlegelberger B, Döhner K, Döhner H, Schlenk RF, Ganzer A. *J Clin Oncol*. 2009 Jun 20;27(18):3000-6. Epub 2009 Apr 20.
- (5) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganzer A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group. *N Engl J Med*. 2008 May 1;358(18):1909-18.
- (6) Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F. *Blood*. 2009 Feb 26;113(9):1875-91. Epub 2008 Sep 23. Review.
- (7) <https://www.uni-ulm.de/onkologie/AMLSG/index.html>
- (8) ClinicalTrials.gov: NCT00783653
- (9) A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Fiedler W, Serve H, Döhner H, Schwittay M, Ottmann OG, O'Farrell AM, Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, Scigalla P, Berdel WE, Hossfeld DK. *Blood*. 2005 Feb 1;105(3):986-93. Epub 2004 Sep 30.
- (10) ClinicalTrials.gov: NCT00850382
- (11) KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K, Schoch C. *Blood*. 2006 Mar 1;107(5):1791-9.
- (12) Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA, Bloomfield CD; Cancer and Leukemia Group B. *J Clin Oncol*. 2006 Aug 20;24(24):3904-11.
- (13) Bullinger et al. *NEJM* 2004
- (14) Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC.
- (15) ClinicalTrials.gov: NCT00893399

- (16) Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Schlenk RF, Döhner K, Kneba M, Götze K, Hartmann F, Del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, Haddank M, Späth D, Groner S, Krebs B, Kayser S, Corbacioglu A, Anhalt A, Benner A, Fröhling S, Döhner H; German-Austrian AML Study Group (AMLSG). *Haematologica*. 2009 Jan;94(1):54-60. Epub 2008 Dec 4.
- (17) *N Engl J Med* 2005
- (18) Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Schlenk RF, Döhner K. *Curr Opin Hematol*. 2009 Mar;16(2):98-104.
- (19) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group., *Lancet Oncol*. 2009

Beitrag von Seite 24:

Ostdeutsche Studiengruppe Hämatologie und Onkologie (OSHO)

Dietger Niederwieser

- (1) Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Basara N, Schulze A, Wedding U, Mohren M, Gerhardt A, Junghanss C, Peter N, Dölken G, Becker C, Heyn S, Kliem C, Lange T, Krahl R, Pönisch W, Fricke HJ, Sayer HG, Al-Ali H, Kamprad F, Niederwieser D; East German Study Group Hematology and Oncology (OSHO). *Leukemia*. 2009 Apr;23(4):635-40. Epub 2009 Jan 8

Beitrag von Seite 35:

Genexpressionsanalysen

Andreas Neubauer, Doris Steinemann und Brigitte Schlegelberger

- (1) Steinemann D, Cario G, Stanulla M, et al. Copy number alterations in childhood acute lymphoblastic leukemia and their association with minimal residual disease. *Genes Chromosomes Cancer*. 2008;47:471-480.
- (2) Staal FJ, Cario G, Cazzaniga G, et al. Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. *Leukemia*. 2006;20:1385-1392.
- (3) Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N Engl J Med*. 2001;344:1031-1037.
- (4) Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *N Engl J Med*. 2006;355:2408-2417.
- (5) O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med*. 2003;348:994-1004.
- (6) Burchert A, Wölfl S, Schmidt M, et al. Interferon alpha, but not the ABL-kinase inhibitor imatinib (STI571) induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. *Blood*. 2003;101:259-264.
- (7) Burchert A, Neubauer A. Interferon alpha and T-cell responses in chronic myeloid leukemia. *Leuk Lymphoma*. 2005;46:167-175.

- (8) Kronenwett R, Butterweck U, Steidl U, et al. Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia. *Oncogene*. 2005;24:5313-5324.
- (9) Zheng C, Li L, Haak M, et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. *Leukemia*. 2006;20:1028-1034.
- (10) Crossman LC, Mori M, Hsieh YC, et al. In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. *Haematologica*. 2005;90:459-464.
- (11) Frank O, Brors B, Fabarius A, et al. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. *Leukemia*. 2006;20:1400-1407.
- (12) Wang Y, Cai D, Brendel C, et al. Adaptive secretion of the Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) mediates Imatinib- and Nilotinib-resistance in BCR/ABL-positive progenitors via JAK-2/STAT-5 pathway activation. *Blood*. 2007;109:2147-2155.